Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

letter

. 2023 Jun 2;33(6):e13177. doi: 10.1111/bpa.13177

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2023 Fourth Military Medical University. Brain Pathology published by John Wiley & Sons Ltd on behalf of International Society of Neuropathology.

This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.

PMC Copyright notice

Radiological, pathological and molecular features of Case 2. (A) Axial FLAIR and contrast‐enhanced T1‐weighted MRI sequences showed a large and heterogeneous enhancement of the mass in the right frontotemporal lobe with an obvious mass effect. H&E staining revealed a heterogeneous appearance: (B) The tumour cells were ovoid in shape and densely arranged in sheets with a branching capillary network. (C) Some areas showed a high‐grade ependymoma‐like structure with brisk mitosis. (D) Palisading necrosis was evident. (E) Microcyst patterns are observable. The tumour cells were diffusely immunopositive for CD56 (F) and SATB2 (I), focally positive for Oligo‐2 (H) and weakly positive for BCOR (G). (J,K) Schematic diagram and validation of EP300::BCOR fusion in Case 2: BCOR (blue) and EP300 (purple) with breakpoints (the red line) are shown and confirmed.